Sotera Health (NASDAQ:SHC) Issues Earnings Results

Sotera Health (NASDAQ:SHC - Get Free Report) issued its earnings results on Thursday, May 1st. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.02, Briefing.com reports. The company had revenue of $254.52 million during the quarter, compared to analysts' expectations of $245.56 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The firm's quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.13 EPS. Sotera Health updated its FY 2025 guidance to 0.700-0.760 EPS.

Sotera Health Trading Up 0.6 %

Shares of SHC stock traded up $0.08 during mid-day trading on Thursday, reaching $13.23. The company's stock had a trading volume of 1,011,205 shares, compared to its average volume of 1,209,826. The firm has a market capitalization of $3.76 billion, a PE ratio of 52.92 and a beta of 1.88. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. Sotera Health has a 12-month low of $9.53 and a 12-month high of $17.08. The company's 50 day simple moving average is $11.39 and its 200-day simple moving average is $12.98.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on SHC shares. Barclays dropped their price objective on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and boosted their price target for the company from $14.00 to $17.00 in a research report on Monday. Finally, Piper Sandler cut their target price on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $15.80.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.